Acute Leukemia Mini Panel – Comprehensive Genetic Testing for Leukemia Detection
Understanding Acute Leukemia Genetic Testing
The Acute Leukemia Mini Panel represents a breakthrough in molecular diagnostics for hematological malignancies. This advanced genetic screening test utilizes Real-Time PCR technology to detect specific chromosomal abnormalities that are critical for diagnosing and classifying acute leukemias. By identifying these genetic markers, healthcare providers can deliver more precise diagnoses and develop targeted treatment strategies.
What Does the Acute Leukemia Mini Panel Detect?
This comprehensive panel screens for seven essential genetic abnormalities associated with acute leukemia:
- AML/ETO (t8;21) – Associated with acute myeloid leukemia with favorable prognosis
- INV16 (CBFB-MYH11) – Core-binding factor leukemia with unique treatment response
- PML/RARA (t15;17) – Acute promyelocytic leukemia requiring specific therapy
- BCR/ABL (Philadelphia Chromosome) – Present in both ALL and CML cases
- TEL/AML1 (ETV6-RUNX1) – Common in childhood ALL with good prognosis
- MLL Rearrangements – Associated with aggressive leukemia subtypes
- E2A Rearrangements – Important for B-cell ALL classification
Who Should Consider This Genetic Test?
This test is recommended for individuals presenting with:
- Unexplained fatigue, weakness, or persistent fever
- Frequent infections or unusual bleeding/bruising
- Bone pain or joint discomfort
- Enlarged lymph nodes, spleen, or liver
- Abnormal complete blood count results
- Family history of hematological malignancies
- Suspected leukemia based on clinical presentation
Key Benefits of Acute Leukemia Genetic Testing
- Accurate Diagnosis: Provides definitive genetic confirmation of leukemia subtypes
- Prognostic Information: Helps predict disease course and treatment response
- Treatment Guidance: Enables selection of targeted therapies based on genetic markers
- Minimal Residual Disease Monitoring: Allows tracking of treatment effectiveness
- Early Detection: Identifies genetic abnormalities before full disease manifestation
Understanding Your Test Results
Your results will indicate the presence or absence of specific genetic abnormalities. A positive result for any of the tested markers provides crucial information for:
- Disease Classification: Determining the exact type of leukemia
- Risk Stratification: Assessing disease aggressiveness and prognosis
- Therapeutic Decisions: Guiding chemotherapy and targeted therapy choices
- Monitoring Strategy: Establishing baseline for treatment response assessment
Negative results help rule out common genetic abnormalities and may suggest alternative diagnoses.
Test Information and Pricing
| Test Component | Details |
|---|---|
| Test Name | Acute Leukemia Mini Panel – AML/ETO, INV16, PML/RARA, BCR/ABL, TEL/AML1, MLL, E2A |
| Discount Price | $244 USD |
| Regular Price | $326 USD |
| Turnaround Time | 5-6 Days |
| Sample Type | Bone marrow / Peripheral blood (Transport immediately) |
| Test Components | EDTA Vacutainer (2ml) |
| Methodology | Real Time PCR |
Nationwide Testing Availability
We have diagnostic centers conveniently located across the United States, including major metropolitan areas such as New York, Los Angeles, Chicago, Houston, Phoenix, Philadelphia, San Antonio, San Diego, Dallas, and San Jose. Our state-of-the-art facilities ensure consistent, high-quality testing standards nationwide.
Take Action for Your Health Today
Early genetic detection of leukemia can significantly impact treatment outcomes and survival rates. Don’t wait for symptoms to progress – proactive testing provides the information needed for timely intervention and personalized care strategies.
Ready to schedule your Acute Leukemia Mini Panel? Contact our genetic specialists today at +1(267) 388-9828 or book your appointment online. Our team is available to answer your questions and guide you through the testing process.
Note: This test requires a doctor’s prescription for diagnostic purposes. Prescription requirements do not apply for surgical clearance, pregnancy-related testing, or international travel documentation.
